RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Short Interest Down 40.5% in July

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 201 shares, a drop of 40.5% from the June 30th total of 338 shares. Based on an average daily volume of 338 shares, the short-interest ratio is presently 0.6 days. Approximately 0.0% of the shares of the stock are short sold.

RCN Pareto Strategic Allocation ETF Stock Down 0.3%

PRTO opened at $27.12 on Friday. The firm has a market cap of $601.49 million, a PE ratio of -28.25 and a beta of 0.60. RCN Pareto Strategic Allocation ETF has a one year low of $24.68 and a one year high of $28.16.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.